Becton, Dickinson and Company (NYSE:BDX – Get Free Report) CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Becton, Dickinson and Company Stock Performance
NYSE:BDX opened at $183.16 on Friday. The company has a market capitalization of $50.47 billion, a price-to-earnings ratio of 55.17, a PEG ratio of 12.93 and a beta of 0.19. The business has a 50 day moving average of $157.84 and a 200 day moving average of $161.70. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
Wall Street Analysts Forecast Growth
BDX has been the subject of several recent research reports. Royal Bank Of Canada boosted their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday. UBS Group started coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price for the company. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Finally, Bank of America reduced their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $185.67.
View Our Latest Analysis on Becton, Dickinson and Company
Institutional Investors Weigh In On Becton, Dickinson and Company
Large investors have recently added to or reduced their stakes in the company. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company during the third quarter worth about $25,000. SHP Wealth Management purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $26,000. Meeder Asset Management Inc. raised its position in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD bought a new position in Becton, Dickinson and Company during the 1st quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc purchased a new stake in Becton, Dickinson and Company in the 2nd quarter worth approximately $29,000. Institutional investors own 86.97% of the company’s stock.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
